
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliation: Department of Surgery, Faculty of Medicine, The University of Hong Kong
Requests for reprints: Anthony Po-Wing Yuen, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR China. Phone: 2819-9604; Fax: 2855-3464; E-mail: thiansze{at}graduate.hku.hk.
| Abstract |
|---|
|
|
|---|
Experimental Design: Expression levels of 156 human mature microRNAs were examined using real-time quantitative PCR (Taq Man MicroRNA Assays; Human Panel) on laser microdissected cells of 4 tongue carcinomas and paired normal tissues. Expression of mature miR-184 was further validated in 20 paired tongue SCC and the normal tissues. Potential oncogenic functions of miR-184 were evaluated in tongue SCC cell lines (Cal27, HN21B, and HN96) with miR-184 inhibitor. Plasma miR-184 levels were evaluated using real-time quantitative PCR.
Results: Using 3-fold expression difference as a cutoff level, we identified 24 up-regulated mature miRNAs including miR-184, miR-34c, miR-137, miR-372, miR-124a, miR-21, miR-124b, miR-31, miR-128a, miR-34b, miR-154, miR-197, miR-132, miR-147, miR-325, miR-181c, miR-198, miR-155, miR-30a-3p, miR-338, miR-17-5p, miR-104, miR-134, and miR-213; and 13 down-regulated mature miRNAs including miR-133a, miR-99a, miR-194, miR-133b, miR-219, miR-100, miR-125b, miR-26b, miR-138, miR-149, miR-195, miR-107, and miR-139. Overexpression of miR-184 was further validated in 20 paired tongue SCC and normal tissues (P = 0.002). Inhibition of miR-184 in tongue SCC cell lines could reduce cell proliferation rate. Down-regulation of c-Myc was observed in two cell lines in response to miR-184 inhibitor. Suppressing miR-184 could induce apoptosis in all three cell lines. Plasma miR-184 levels were significantly higher in tongue SCC patients in comparison with normal individuals, and the levels were significantly reduced after surgical removal of the primary tumors.
Conclusions: Overexpression of miR-184 might play an oncogenic role in the antiapoptotic and proliferative processes of tongue SCC. In addition, plasma miR-184 levels were associated with the presence of primary tumor. Further studies on the aberrantly expressed miRNAs in tongue SCC as well as using plasma miRNAs as novel tumor markers are warranted.
50% patients were already in advanced stage III and IV on presentation (1, 2). The understanding of the molecular pathways of carcinogenesis or progression would be helpful in improving diagnosis, therapy, and prevention of the disease.
MicroRNAs (miRNA) are a group of gene-specific regulators. miRNAs are
20-nt long, single-stranded, noncoding RNA molecules (3). They are encoded in long primary forms in the nucleus. The primary miRNAs will be transported into the cytoplasm actively after being processed by cellular nucleases, e.g., Drosha. Cytoplasmic miRNAs are then processed by Dicer into the mature forms. Mature miRNAs are associated with a cellular complex that is similar to the RNA-induced silencing complex for RNA interference (4, 5). Mature miRNAs could regulate protein expression at posttranscriptional levels through direct binding to specific messenger RNA molecules. The specific binding of miRNAs could promote degradation of mRNA and/or hinder the translation process.
Dysregulation of miRNAs is common in various cancers. The dysregulated miRNAs play a role in carcinogenesis or tumor progression by altering the normal gene expression patterns. One example is miR-21. In human glioblastoma cells, caspase cascade was inactivated by the up-regulated miR-21 (6). Inhibiting miR-21 could increase chemosensitivity of malignant cholangiocytes (7). MiR-21 could also modulate tumor growth through regulation of bcl-2 expression (8).
In view of the limited data on miRNA expression patterns and their functional roles in various human cancers including tongue carcinoma, we aimed at identifying the aberrantly expressed miRNAs in tongue SCC. Because cell-free RNA (originated from the primary tumor) could be detected in the circulation of cancer patients, we also examined whether the aberrantly expressed miRNA could be detected in the circulation of patients with tongue SCC.
| Materials and Methods |
|---|
|
|
|---|
Laser microdissection. Ornithine carbamyl transferase–embedded frozen tissues were sectioned at a thickness of 8 µm and mounted onto PALM membrane slides pretreated with RNase-zap (Ambion).The slides were fixed in 70% ethanol, stained with Mayer's H&E, and dehydrated sequentially in increasing concentrations of ethanol and xylene (followed by 3 min of air drying). PALM microbeam system (P.A.L.M.) was used to procure pure cell populations of either cancer cells or normal epithelial cells until 25,000 to 30,000 cells were collected for each population in each patient. The microdissected cells were then transferred to lysis buffer (provided in the miRNA isolation kit listed below) for miRNA extraction. A total of four cases of tongue SCC and matched normal epithelia were processed. There were 3 male and 1 female patients (age range, 44-66 years). The pathologic stages were 1 T2N1M0 and 3 T3N2M0.
Cell lines. Tongue SCC cell line Cal27 was purchased from American Type Culture Collection. HN21B and HN96 were short-term cultures derived from tongue SCC tissues in our laboratory. All the cell lines were maintained in RPMI 1640 with 10% fetal bovine serum.
RNA extraction. miRNAs of tissues, cultured cells, and plasma were extracted and purified using mirVana miRNA Isolation kit (Ambion) following the manufacturer's instructions.
Quantitative reverse transcription-PCR of mature miRNAs. miRNA expression patterns were evaluated using Taq Man MicroRNA Assays, Human Panel (Applied Biosystems). The assay includes two steps: generation of cDNA by reverse transcription reaction and Taq Man real-time PCR assay. In brief, miRNAs in the samples were converted into cDNA using 156 specific stem-loop reverse transcription primers. After cDNA conversion, the quantity of mature miRNAs was evaluated using specific Taq Man real-time PCR primers and probes. Real-time PCR was done using GeneAmp Fast PCR Master Mix (Applied Biosystems) and ABI 7900HT real-time PCR machine. All reactions were done in duplicate. Expression levels of mature mRNAs were evaluated using comparative CT method (2–
CT). Transcription level of miR-16 was used as endogenous control. Theory of the real-time PCR assay and the list of the human miRNAs could be found on the company's Web site.1
Small interfering RNA transfection. Mature miR-184 inhibitor was obtained from Ambion. Cells were seeded at 20,000 per well in chamber slides. Inhibitor was transfected into the cell lines using siPORT NeoFX reagent (Ambion) following manufacturer's instructions. Culture medium was changed after 24 h of transfection. Transfection effects were evaluated after 72 h. The treatment was done in triplicate. Cells treated with the transfection reagent only were used as mock control.
Cell proliferation assay. Cell proliferation assay was done using Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's protocol.
Immunocytochemistry. Tongue SCC cell lines were seeded into chamber slides and transfected with miR-184 inhibitor as described above. After 72 h, the cells were rinsed with PBS and fixed in 4% paraformaldehyde for 30 min at room temperature. After being permeabilized with 0.2% Triton X-100 for 5 min, the cells were blocked with 1% bovine serum albumin for 1 h at room temperature. The cells were then incubated with mouse monoclonal anti–c-Myc (Ab-2; 1:100; Calbiochem) for 1 h at room temperature. Cells were washed and incubated with horseradish peroxidase–labeled polymer conjugated to goat anti-mouse immunoglobulins (Envision; DAKO) for 45 min at room temperature. After additional PBS washing, the slides were developed with 3,3'-diaminobenzidine and couterstained with hematoxylin. C-Myc protein was expressed in the nuclei. The positive cells were counted in five randomly selected fields and expressed as percentage of total cells counted.
Terminal deoxynucleotidyl-transferase–mediated dUTP nick-end labeling. Apoptosis was determined using the terminal deoxynucleotidyl-transferase–mediated dUTP nick-end labeling (TUNEL) assay after transfection for 72 h. Briefly, the cells were rinsed with PBS and fixed in 4% paraformaldehyde for 25 min at room temperature. After permeabilized with 0.2% Triton X-100 for 5 min, the slides were incubated with equilibration buffer for 10 min. Then, rTdT reaction mix was applied to the cells and the slides were incubated at 37°C for 60 min inside a humidified chamber. The reaction was terminated with 2 x SCC for 15 min at room temperature. After blocking the activity of endogenous peroxidase with 0.3% hydrogen peroxide for 5 min, the slides were incubated with Streptavidin horseradish peroxidase for 30 min and then developed with 3,3'-diaminobenzidine. Coverslips were mounted and the results were observed under the microscope. The apoptotic nuclei were stained as dark brown. Positive-labeled cells were counted in five randomly selected fields and expressed as percentage of total cells counted.
Statistical analysis. The statistical association between miRNAs levels and the disease groups was examined by Wilcoxon signed-ranks test. P values of <0.05 were considered as statistical significant. All P values were two-sided. Data analysis was done using SPSS for Windows version 14.0 (SPSS, Inc.).
| Results |
|---|
|
|
|---|
|
|
Cellular response to miR-184 inhibition. The three tongue SCC cell lines were transfected with miR-184 inhibitor. Cultured cells transfected with miR-184 were relatively smaller and denser compared with control cultures (Fig. 1 ). The proliferation rate was reduced in all three cell lines after transfection with miR-184 inhibitor compared with controls (Fig. 2 ). Immunostaining of c-Myc showed that c-Myc–positive cells were significantly reduced in Cal27 (34% versus 76%) and HN96 (32% versus 78%) cell lines after transfection with miR-184 inhibitor (all P < 0.05; Mann-Whitney U test; Fig. 3 ). Apoptosis was detected by in situ TUNEL assay (Fig. 4 ). The percentages of apoptotic cells were significantly higher (all P < 0.05; Mann-Whitney U test) in miR-184 suppressed cell lines compared with the mock controls: Cal27 (10.64% versus 0.35%), HN21B (7.05% versus 0.62%), and HN96 (9.25% versus 0.78%).
|
|
|
|
Unlike the control MiR-16, which was found in both cancer patients and normal individuals, mature miR-184 could only be detected in 80% (24 of 30) cancer patients and 13% (5 of 38) normal individuals. The plasma level of miR-184 was significantly higher (Mann-Whitney U test; P < 0.001; 95% confidence interval, 0.72-1,488.04) in cancer patients (median, 398.46; range 6.89-9,699.56) compared with the normal individuals (median, 0.27; range, 0.02-72.19). We further evaluated the changes in plasma miR-184 levels in the patients after the surgical removal of the primary tumor. Twenty-five patients had both preoperative and postoperative plasma available for this study (Table 3 ). The mean plasma levels reduced from 1,801.30 before operation to 177.84 after operation (P < 0.001; Wilcoxon signed-ranks test).
|
| Discussion |
|---|
|
|
|---|
Mature miR-184 expression has been reported in basal and immediately suprabasal cells of the corneal epithelium in mouse model. Using in situ hybridization, Ryan et al. (10) showed that miR-184 was more strongly expressed in the epithelial cells of the germinative zone. So far, dysregulation of miR-184 has not been reported in human cancers. Therefore, we were interested to validate its roles in tongue SCC after the aberrant overexpression of miR-184 was further confirmed in paired tongue carcinomas and normal tissues.
To study the functional roles of miR-184 in tongue carcinoma, we knocked down the expression of miR-184 in the tongue SCC cell lines using the specific inhibitor. Morphologically, the cells became round and condensed, suggesting that miR-184 inhibitor might induce cell death in tongue SCC cells. To validate this potential cell death–inducing effect, TUNEL staining was done. The significant increase in apoptotic cells in response to miR-184 inhibitor suggested an antiapoptotic function of mature miR-184. Moreover, we observed that the total cell numbers were obviously reduced in the presence of miR-184 inhibitor. To examine the potential association between miR-184 and cell proliferation, cell proliferation assay and c-Myc staining were done. Our results indicated that miR-184 may hinder tongue SCC cell proliferation partly through altering c-Myc expression. Taken together, our results suggested that miR-184 might play a part in both antiapoptotic and proliferative processes of tongue SCC cells.
RNAs derived from tumor cells could be absorbed into the peripheral blood of cancer patients and become detectable as cell-free surrogate tumor markers (11, 12). There is no report on plasma cell–free miRNA in cancer patients yet. Thus, we were interested to know whether the up-regulated miRNA in cancer cells could be absorbed into the systemic circulation as cell-free miRNA tumor marker in the patients. We first examined whether mature miRNA was detectable in the plasma of both normal individuals and cancer patients. We found that miR-16, the house-keeping miRNA, was detectable in all the plasma samples recruited from both normal individuals and tongue SCC patients. In contrast to the miR-16, miR-184 was not detected in all the plasma samples. Plasma miR-184 was detected in 13% of the normal individuals. In comparison, plasma miR-184 was more frequently detected (80%) in tongue SCC patients. In addition, plasma miR-184 levels were significantly higher in patients with tongue SCC in comparison with the normal individuals. The results suggested that the increased miR-184 in SCC patients may be related to the presence of primary tumor. Furthermore, the plasma miR-184 levels were
10-fold reduced after the surgical removal of tumor. Thus, we hypothesized that the higher plasma miRNA levels were due to absorption of the miRNA into the circulation from a large number of cancer cells with highly expressed miR-184 in the body before surgery. The plasma level therefore reduced significantly after the surgical removal of the tumor. The reduction of plasma miR-184 levels further confirmed the correlation between overexpressed miR-184 and the primary tongue SCC. Whether plasma miRNAs could be used as sensitive and specific surrogate tumor markers requires further studies in serially taken blood samples of larger cohort of patients with long term follow-up.
Increased levels of plasma DNA/RNA have been observed in cancer patients. In our cohort of tongue SCC patients, miR-184 levels were elevated in the plasma before operation and reduced significantly after surgical treatment. The reduction is likely because of the removal of the primary tumor, the origin of the oncogenic miRNAs. However, the reduction was not an absolute event in all the patients after operation. We observed that three patients (patients 4, 17, and 22) showed an increase in plasma miR-184 after the operation. We tried to correlate the increase with the clinicopathologic variables but no associations were found. There are several possible explanations for this phenomenon. First, because all of the three patients had their blood taken within 1 month after operation (day 3, 24, and 25, respectively), the high-plasma miRNA might be partly due to the absorption of large amount of nucleic acids including miRNA into the circulation immediately after the major surgery. Second, the high-plasma miR-184 might come from microscopic residues or occult tumors. All the patients had no local recurrence or distant metastasis at the time when the peripheral blood was collected. Longer follow-up period are required to validate this assumption. In addition, their plasma miRNAs might result from other complications. For instance, increased plasma nucleic acids have been reported in noncancer disorders such as stroke, trauma, myocardial infarction, autoimmune disorders, and premalignant complications (13). This should be taken into account when using plasma miRNAs to monitor cancer patients.
In conclusion, there were aberrantly expressed miRNAs in tongue SCC. MiR-184 is a candidate oncogenic miRNA in tongue SCC and might play a part in the antiapoptosis and proliferation of tongue SCC cells. Further identification of aberrantly expressed miRNAs and the elucidation of their functional roles are helpful in the understanding of the pathogenesis of this disease. It is also worth studying the clinical values of plasma miRNAs as surrogate tumor markers.
| Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: T.-S. Wong and X.-B. Liu contribute equally to the work.
1 http://mirna.appliedbiosystems.com ![]()
Received 3/21/07; revised 11/20/07; accepted 12/28/07.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. P. Weitzel, M. L. Lesniewski, P. Haviernik, S. Kadereit, P. Leahy, N. J. Greco, and M. J. Laughlin microRNA 184 regulates expression of NFAT1 in umbilical cord blood CD4+ T cells Blood, June 25, 2009; 113(26): 6648 - 6657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, H. Huang, L. Sun, M. Yang, C. Pan, W. Chen, D. Wu, Z. Lin, C. Zeng, Y. Yao, et al. MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor Clin. Cancer Res., June 15, 2009; 15(12): 3998 - 4008. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Margulies, D. P. Bednarik, and D. L. Dries Genomics, transcriptional profiling, and heart failure. J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1752 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, and X. ZHOU MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines Cancer Genomics Proteomics, May 1, 2009; 6(3): 131 - 139. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |